The Cigna (CI) concentration risks

The company's concentration profile spans both supplier and customer dimensions, with all disclosed exposures carrying a medium-share size band — indicating a moderate rather than dominant share in each case. On the supply side, the pharmaceutical distribution channel shows notable dependency: the Evernorth Health Services segment uses one wholesaler for approximately half of pharmaceutical purchases, concentrating procurement through a single intermediary. While the half-share language implies scale, the disclosed size band is moderate, and switching is theoretically possible, though operationally disruptive. On the customer side, three clients each drive significant revenues. Centene Corporation has a multiyear agreement with Express Scripts, Prime Therapeutics LLC has agreements in place, and TRICARE — the military health care program — represents the third major relationship. Each is a moderate-share dependency by disclosed size; together they reflect meaningful revenue concentration in large managed care and government health plan counterparties. The TRICARE relationship carries a mixed character, as government program continuity is partly structural but also subject to contract renewal risk. Complementing these is a pharmacy network concentration: the ten largest retail pharmacy chains represent approximately 47% of the total number of stores in the company's largest network — a moderate-share dependency on a small number of large pharmacy operators. In aggregate, the profile describes a company whose critical commercial relationships — in procurement, customer revenue, and network access — are each moderately concentrated, with dependency character across most dimensions.

For the engine’s reasoning on CI’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.